GlassScriptPhysician profile
Martin Majer
NPI 1376749234
$7,219.09
in general payments reported to CMS, 2019-2025
46 companies · $3,271 in 2025
The $3,271 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $135 · 2021: $251 · 2022: $148 · 2024: $2,865 · 2025: $3,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,730 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,729.95 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $126.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,667.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $643.58 | 2020-2025 | Imfinzi, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $432.83 | 2019-2025 | Opdivo, Reblozyl |
| Abbvie INC. | $382.27 | 2024-2025 | |
| Incyte Corporation | $345.54 | 2024-2025 | Jakafi, Jakafi, Monjuvi |
| Merck Sharp & Dohme LLC | $326.07 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $320.98 | 2021-2025 | Erleada, Talvey, Akeega |
| Pfizer INC. | $250.34 | 2019-2025 | |
| Celgene Corporation | $228.99 | 2024-2025 | Pomalyst, Reblozyl |
| Eisai INC. | $223.91 | 2024-2025 | |
| Astellas Pharma US INC | $217.28 | 2019-2025 | Xtandi |
| Glaxosmithkline, LLC. | $184.42 | 2024-2025 | Jemperli, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $153.37 | 2024-2025 | |
| Genentech USA, INC. | $140.76 | 2019-2024 | Lunsumio, Polivy, Columvi |
| Gilead Sciences, INC. | $127.67 | 2021-2025 | Trodelvy |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $121.39 | 2024-2025 | |
| Daiichi Sankyo INC. | $115.89 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Karyopharm Therapeutics INC. | $115.35 | 2024-2025 | Xpovio |
| Array Biopharma INC | $98.56 | 2024-2025 | Mektovi, Tukysa, Braftovi |
| Agios Pharmaceuticals, INC. | $85.71 | 2024-2025 | Pyrukynd |
| Puma Biotechnology, INC. | $75.57 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $70.00 | 2024 | Provenge |
| Takeda Pharmaceuticals U.S.A., INC. | $69.17 | 2019 | |
| Stemline Therapeutics INC. | $62.54 | 2024 | Orserdu |
| Lilly USA, LLC | $59.14 | 2024 | Jaypirca, Verzenio |
| Pharmaessentia USA Corporation | $58.28 | 2025 | Besremi |
| Beigene USA, INC. | $57.32 | 2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $56.51 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Regeneron Healthcare Solutions, INC. | $53.71 | 2024-2025 | Libtayo |
| Tempus Ai, INC | $52.13 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.03 | 2025 | |
| Emd Serono, INC. | $36.48 | 2025 | |
| Verity Pharmaceuticals INC. | $33.98 | 2025 | Trelstar |
| Adaptive Biotechnologies Corporation | $33.75 | 2024 | Clonoseq |
| Springworks Therapeutics, INC. | $32.59 | 2024 | Ogsiveo |
| Alexion Pharmaceuticals, INC. | $31.35 | 2025 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $28.60 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $25.99 | 2024 | Somatuline Depot, Onivyde |
| Legend Biotech USA INC. | $24.69 | 2024 | |
| Geron Corporation | $23.74 | 2025 | Rytelo |
| Myriad Genetic Laboratories, INC. | $21.03 | 2025 | Myrisk |
| Kyowa Kirin, INC. | $19.08 | 2025 | |
| Octapharma USA, INC. | $18.69 | 2024 | Octagam Immune Globulin (Human) |
| Azurity Pharmaceuticals, INC. | $18.17 | 2025 | Danziten, Vivimusta |
| Sumitomo Pharma America, INC. | $15.38 | 2025 | Orgovyx |
| Servier Pharmaceuticals LLC | $15.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Majer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.